| [1] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
|
| [2] |
中华人民共和国卫生和计划生育委员会医政医管局．原发性肝癌诊疗规范（2017年版）[J]．中华肝脏病杂志，2017，25(12): 886-895.
|
| [3] |
Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127):1301-1314.
|
| [4] |
Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma[J]. Gastroenterology, 2016, 150(4):835-853.
|
| [5] |
Jiang C, Davalos RV, Bischof JC. A review of basic to clinical studies of irreversible electroporation therapy[J]. IEEE Trans Biomed Eng, 2015, 62(1):4-20.
|
| [6] |
Davalos RV, Mir IL, Rubinsky B. Tissue ablation with irreversible electroporation[J]. Ann Biomed Eng, 2005, 33(2):223-231.
|
| [7] |
Rubinsky B. Irreversible electroporation in medicine[J]. Technol Cancer Res Treat, 2007, 6(4):255-260.
|
| [8] |
Golberg A, Bruinsma BG, Uygun BE, et al. Tissue heterogeneity in structure and conductivity contribute to cell survival during irreversible electroporation ablation by "electric field sinks"[J]. Sci Rep, 2015(5):8485.
|
| [9] |
Frühling P, Nilsson A, Duraj F, et al. Single-center nonrandomized clinical trial to assess the safety and efficacy of irreversible electroporation (IRE) ablation of liver tumors in humans: short to mid-term results[J]. Eur J Surg Oncol, 2017, 43(4):751-757.
|
| [10] |
Zimmerman A, Grand D, Charpentier KP. Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives[J].J Hepatocell Carcinoma, 2017(4):49-58.
|
| [11] |
Niessen C, Igl J, Pregler B, et al. Factors associated with short-term local recurrence of liver cancer after percutaneous ablation using irreversible electroporation: a prospective single-center study[J].J Vasc Interv Radiol, 2015, 26(5):694-702.
|
| [12] |
Herwald SE, Chen JH, Arellano RS. Irreversible electroporation for treatment of hepatocellular carcinoma adjacent to the gallbladder[J]. J Vasc Interv Radiol, 2016, 27(7):1093-1094.
|
| [13] |
Distelmaier M, Barabasch A, Heil P, et al. Midterm safety and efficacy of irreversible electroporation of malignant liver tumors located close to major portal or hepatic veins[J]. Radiology, 2017, 285(3):1023-1031.
|
| [14] |
Sutter O, Calvo J, N'Kontchou G, et al. Safety and efficacy of irreversible electroporation for the treatment of hepatocellular carcinoma not amenable to thermal ablation techniques: a retrospective single-center case series[J]. Radiology, 2017, 284(3):877-886.
|
| [15] |
Cheung W, Kavnoudias H, Roberts S, et al. Irreversible electroporation for unresectable hepatocellular carcinoma: initial experience and review of safety and outcomes[J]. Technol Cancer Res Treat, 2013, 12(3):233-241.
|
| [16] |
Faroja M, Ahmed M, Appelbaum L, et al. Irreversible electroporation ablation: is all the damage nonthermal?[J]. Radiology, 2013, 266(2):462-470.
|
| [17] |
Adeyanju OO, Al-Angari HM, Sahakian AV. The optimization of needle electrode number and placement for irreversible electroporation of hepatocellular carcinoma[J]. Radiol Oncol, 2012, 46(2):126-135.
|
| [18] |
Beyer LP, Pregler B, Michalik K, et al. Evaluation of a robotic system for irreversible electroporation (IRE) of malignant liver tumors: initial results[J]. Int J Comput Assist Radiol Surg, 2017, 12(5):803-809.
|
| [19] |
Beyer LP, Pregler B, Nießen C, et al. Stereotactically-navigated percutaneous Irreversible Electroporation (IRE) compared to conventional IRE: a prospective trial[J]. PeerJ, 2016(4):e2277.
|
| [20] |
Lee EW, Wong D, Prikhodko SV, et al. Electron microscopic demonstration and evaluation of irreversible electroporation-induced nanopores on hepatocyte membranes[J]. J Vasc Interv Radiol, 2012, 23(1):107-113.
|
| [21] |
Lee EW, Chen C, Prieto VE, et al. Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation[J]. Radiology, 2010, 255(2):426-433.
|
| [22] |
朱统寅，孙军辉，陈新华，等．CT导引纳米刀消融猪肝脏可行性实验研究[J]．介入放射学杂志，2016，25(4):337-340.
|
| [23] |
Miller L, Leor J, Rubinsky B. Cancer cells ablation with irreversible electroporation[J]. Technol Cancer Res Treat, 2005, 4(6):699-705.
|
| [24] |
Guo Y, Zhang Y, Klein R, et al. Irreversible electroporation therapy in the liver: longitudinal efficacy studies in a rat model of hepatocellular carcinoma[J]. Cancer Res, 2010, 70(4):1555-1563.
|
| [25] |
Onik G, Rubinsky B. Irreversible electroporation: first patient experience focal therapy of prostate cancer (irreversible electroporation)[M]. Berlin Heidelberg: Springer, 2010.
|
| [26] |
黄凯文．履险如夷之纳米刀肝癌消融[J/CD]．肝癌电子杂志, 2015，2(2):36-41.
|
| [27] |
Bhutiani N, Philips P, Scoggins CR, et al. Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC)[J]. HPB, 2016, 18(7):593-599.
|
| [28] |
Sugimoto K, Moriyasu F, Kobayashi Y, et al. Irreversible electroporation for nonthermal tumor ablation in patients with hepatocellular carcinoma: initial clinical experience in Japan[J]. Jpn J Radiol, 2015, 33(7):424-432.
|
| [29] |
Zeng J, Liu G, Li ZH, et al. The safety and efficacy of irreversible electroporation for large hepatocellular carcinoma[J]. Technol Cancer Res Treat, 2017, 16(1):120-124.
|
| [30] |
Cheng RG, Bhattacharya R, Yeh MM, et al. Irreversible electroporation can effectively ablate hepatocellular carcinoma to complete pathologic necrosis[J]. J Vasc Interv Radiol, 2015, 26(8):1184-1188.
|
| [31] |
Llovet JM, Vilana R, Brú C, et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma[J]. Hepatology, 2001, 33(5):1124-1129.
|
| [32] |
de Baère T, Risse O, Kuoch V, et al. Adverse events during radiofrequency treatment of 582 hepatic tumors[J]. AJR Am J Roentgenol, 2003, 181(3):695-700.
|
| [33] |
Stigliano R, Marelli L, Yu D, et al. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. what is the risk and the outcome? seeding risk for percutaneous approach of HCC[J]. Cancer Treat Rev, 2007, 33(5):437-447.
|
| [34] |
Wong SL, Mangu PB, Choti MA, et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer[J]. J Clin Oncol, 2010, 28(3):493-508.
|
| [35] |
Livraghi T, Solbiati L, Meloni MF, et al. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study[J]. Radiology, 2003, 226(2):441-451.
|
| [36] |
Chen X, Ren Z, Yin S, et al. The local liver ablation with pulsed electric field stimulate systemic immune reaction against hepatocellular carcinoma (HCC) with time-dependent cytokine profile[J]. Cytokine, 2017(93):44-50.
|
| [37] |
Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy[J]. Nat Rev Cancer, 2014, 14(3):199-208.
|
| [38] |
Li X, Xu K, Li W, et al. Immunologic response to tumor ablation with irreversible electroporation[J]. PLoS One, 2012, 7(11):e48749.
|
| [39] |
Neal RE 2nd, Rossmeisl JH Jr, Robertson JL, et al. Improved local and systemic anti-tumor efficacy for irreversible electroporation in immunocompetent versus immunodeficient mice[J]. PLoS One, 2013, 8(5):e64559.
|
| [40] |
Bulvik BE, Rozenblum N, Gourevich S, et al. Irreversible electroporation versus radiofrequency ablation: a comparison of local and systemic effects in a small-animal model[J]. Radiology, 2016, 280(2):413-424.
|